Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05247684
PHASE2

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Sponsor: Akeso

View on ClinicalTrials.gov

Summary

AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC

Official title: Phase II Clinical Study of AK112, an Anti-PD-1 and VEGF Bispecific Antibody, Alone or in Combination With Chemotherapy for the Neoadjuvant/Adjuvant Treatment of Resectable Non-small Cell Lung Cancer

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2022-02-20

Completion Date

2026-12-31

Last Updated

2026-03-05

Healthy Volunteers

No

Interventions

DRUG

AK112

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Paclitaxel

IV infusion

Locations (1)

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China